Biomarkers for intensive care medicine patients: the (stony) path into a bright future?

References

• Amen EM, Becker EM, Truebel H. (2011). Analysis of V/Q–matching – a safety “biomarker“ in pulmonary drug development? Biomarkers 16 (Supplement 1):S5–S10.
   Google Scholar
• Asadullah K, Woiciechowsky C, Döcke WD, Egerer K, Kox WJ, Vogel S, Sterry W, Volk HD. (1995). Very low monocytic HLA-DR expression indicates high risk of infection–immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 2:184–190.
   Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95.
   PubMed Web of Science ®Google Scholar
• Dickson M, Gagnon JP. (2004). Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3:417–429.
   PubMed Web of Science ®Google Scholar
• Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. (1997). Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678–681.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. (2009). Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 27:2962–2969.
   PubMedGoogle Scholar
• Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. (2001). Serial evaluation of the SOFA score to predict outcome in critically ill patients. Jama 286:1754–1758.
   PubMed Web of Science ®Google Scholar
• Goldhill DR, Sumner A. (1998). Outcome of intensive care patients in a group of British intensive care units. Crit Care Med 26:1337–1345.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. (2007). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303–2309.
   PubMed Web of Science ®Google Scholar
• Hughes B. (2008). 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov 7:107–109.
   Google Scholar
• Kramer F, Milting H. (2011). Novel biomarkers in human terminal heart failure and under mechanical circulatory support. Biomarkers 16 (Supplement 1):S31–S41.
   Google Scholar
• Kroll W. (2008). Biomarkers− predictors, surrogate parameters− a concept definition. In: Schmitz G, Endres S, Götte D, eds. Biomarker. Stuttgart: Schattauer, 1–14.
   Google Scholar
• Latour J, Lopez-Camps V, Rodriguez-Serra M, Giner JS, Nolasco A, Alvarez-Dardet C. (1990). Predictors of death following ICU discharge. Intensive Care Med 16:125–127.
   Google Scholar
• Natanson C, Esposito CJ, Banks SM. (1998). The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26:1927–1931.
   PubMed Web of Science ®Google Scholar
• Nfor TK, Walsh TS, Prescott RJ. (2006). The impact of organ failures and their relationship with outcome in intensive care: analysis of a prospective multicentre database of adult admissions. Anaesthesia 61:731–738.
   Google Scholar
• O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. (2005). In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. (2004). Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32:2173–2182.
   PubMed Web of Science ®Google Scholar
• Paulus P, Zacharowski K.. (2011). Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers 16 (supplement 1): S11–S21.
   Google Scholar
• Pharmaceutical Industry Profile. (2010). The Pharmaceutical Research & Manufacturers of America, PhRMA.
   Google Scholar
• Resche-Rigon M, Azoulay E, Chevret S. (2006). Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care 10:R5.
   PubMedGoogle Scholar
• Rowan KM, Kerr JH, Major E, McPherson K, Short A, Vessey MP. (1993). Intensive Care Society’s APACHE II study in Britain and Ireland–II: Outcome comparisons of intensive care units after adjustment for case mix by the American APACHE II method. Bmj 307:977–981.
   PubMed Web of Science ®Google Scholar
• Sawitzki B, Schlickeiser S, Reinke P, Volk HD. (2011). Monitoring tolerance and rejection in organ transplant recipients. Biomarkers 16 (Supplement 1):S42–S50.
   Google Scholar
• Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792.
   PubMed Web of Science ®Google Scholar
• Urbschat A, Obermüller N, Haferkamp A. (2011). Biomarker of Kidney Injury. Biomarkers 16 (Supplement 1):S22–S30.
   Google Scholar
• Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. (1998). Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. (1996). The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710.
   PubMed Web of Science ®Google Scholar
• Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Müller JM, Döcke WD, Kox WJ. (1996). Monocyte deactivation–rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 Suppl 4:S474–S481.
   Google Scholar
• Zeni F, Freeman B, Natanson C. (1997). Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25:1095–1100.
   PubMed Web of Science ®Google Scholar